Liposomes against Alzheimer’s Disease: Current Research and Future Prospects
Open Access
- 8 July 2024
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 12 (7) , 1519
Abstract
Alzheimer’s disease, the most common neurodegenerative disease, affects more than 60 million people worldwide, a number that is estimated to double by 2050. Alzheimer’s disease is characterized by progressive memory loss, the impairment of behavior, and mood changes, as well as the disturbed daily routine of the patient. Although there are some active molecules that can be beneficial by halting the progression of the disease, the blood–brain barrier and other physiological barriers hinder their delivery and, consequently, the appropriate management of the disease. Therefore, drug delivery systems that effectively target and overcome the blood–brain barrier to reach the targeted brain area would improve treatment effectiveness. Liposomes are lipophilic carriers that consist of a phospholipid bilayer structure, simulating the physiological lipidic layer of the blood–brain barrier and enabling better delivery of the drug to the brain. Given that pure liposomes may have less targeting affinity than functionalized liposomes, modification with groups such as lactoferrin, poly(ethylene glycol), and transferrin may improve specificity. In this mini-review, we summarize the literature on the use of liposomes for the treatment of Alzheimer’s disease, focusing on the functionalization moieties of liposomes. In addition, challenges in brain delivery are also discussed.Keywords
This publication has 80 references indexed in Scilit:
- Cell-Based in Vitro Blood–Brain Barrier Model Can Rapidly Evaluate Nanoparticles’ Brain Permeability in Association with Particle Size and Surface ModificationInternational Journal of Molecular Sciences, 2014
- Magnetic nanoparticles: preparation, physical properties, and applications in biomedicineDiscover Nano, 2012
- New Acetylcholinesterase Inhibitors for Alzheimer's DiseaseInternational Journal of Alzheimer's Disease, 2011
- Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease)Journal of Drug Delivery, 2011
- Comparative Permeabilities of the Paracellular and Transcellular Pathways of Corneal Endothelial LayersThe Journal of Membrane Biology, 2011
- Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential2006
- Importance of P-glycoprotein at blood–tissue barriersTrends in Pharmacological Sciences, 2004
- Blood–brain barrier transport of synthetic adenosine A1 receptor agonists in vitro: structure transport relationshipsEuropean Journal of Pharmaceutical Sciences, 2003
- Importance of P‐glycoprotein for drug disposition in humansEuropean Journal of Clinical Investigation, 2003
- Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeabilityJournal of Medicinal Chemistry, 1980